IP Library › Patent Application 13555352
Patent Application
App. No. 13/555,352

USE OF 1-HYDROXY-2- PYRIDONES FOR THE TREATMENT OF SEBORRHEIC DERMATITIS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/555,352
Abstract

Compounds of the formula (1) are disclosed and are suitable for the treatment of seborrheic dermatitis.

Claims (16)

1 - 13 . (canceled)

14 . A solid pharmaceutical formulation comprising

One or more 1-hydroxy-2-pyridones selected from the group consisting of ciclopirox and octopirox; and

One or more surfactants.

15 . The formulation of claim 14 wherein the formulation has a pH of 4.5 to 6.5.

16 . The formulation of claim 14 wherein the 1-hydroxy-2-pyridone is ciclopirox.

17 . The formulation of claim 14 wherein the 1-hydroxy-2-pyridones are present in a concentration of 0.2% to 10% by weight of the formulation.

18 . The formulation of claim 14 wherein the 1-hydroxy-2-pyridones are present in a concentration of 0.5% to 2% by weight of the formulation.

19 . A method of treating seborrheic dermatitis comprising

Wetting and lathering a solid pharmaceutical formulation, wherein the formulation comprises one or more 1-hydroxy-2-pyridones selected from the group consisting of ciclopirox and octopirox; and one or more surfactants,

Applying the formulation to the skin, and

Washing off the formulation.

20 . The method of claim 19 wherein the formulation has a pH of 4.5 to 6.5.

21 . The method of claim 19 wherein the 1-hydroxy-2-pyridone is ciclopirox.

22 . The method of claim 19 wherein the 1-hydroxy-2-pyridones are present in a concentration of 0.2% to 10% by weight of the formulation.

23 . The method of claim 19 wherein the 1-hydroxy-2-pyridones are present in a concentration of 0.5% to 2% by weight of the formulation.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Apr 24, 2013
From: MEDICIS PHARMACEUTICAL CORPORATION
To: GOLDMAN SACHS LENDING PARTNERS LLC
Reel/Frame 030281/0433 →